Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Effect on GPVI in Pediatric ITP
NCT03412188Completed
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of eltrombopag in immune thrombocytopenia (ITP) (2 arms). Primary endpoint: Expression of glycoprotein VI collagen receptor at 24 weeks. Started Aug 2018; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03412188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412188.